Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma

Neoplasia

Volumn 12, Issue 8, 2010, Pages 637-649

  Tap, William D ^a   Gong, Ke Wei ^a   Dering, Judy ^a   Tseng, Yiou ^a   Ginther, Charles ^a   Pauletti, Giovanni ^a   Glaspy, John A ^a   Essner, Richard ^a   Bollag, Gideon ^b   Hirth, Peter ^b   Zhang, Chao ^b   Slamon, Dennis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PLEXXIKON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MELANOCORTIN 1 RECEPTOR; METALLOTHIONEIN; MITOGEN ACTIVATED PROTEIN KINASE; PLX 4032; RAS PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SELECTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GERM LINE; IC 50; MELANOMA; MELANOMA CELL; PHARMACODYNAMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEADY STATE; TUMOR VASCULARIZATION; WESTERN BLOTTING;

EID: 77956029013     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10414     Document Type: Article

References (47)

1. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, et al. (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med 353, 2135-2147.
2. Curtin JA, Busam K, Pinkel D, and Bastian BC (2006). Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24, 4340-4346.
3. Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kanetsky PA, Pinkel D, and Bastian BC (2006). MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313, 521-522.
4. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, et al. (2008). Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99, 734-740.
5. Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, Carberry M, Troxel AB, Letrero R, Nathanson KL, et al. (2009). Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 15, 7711-7718.
6. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron N, and Arbiser JL (2002) Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8, 3728-3733.
7. Gray-Schopfer V, Wellbrock C, and Marais R (2007). Melanoma biology and new targeted therapy. Nature 445, 851-857.
8. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, and Rosen N (2009). (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 106, 4519-4524.
9. Kantrow SM, Boyd AS, Ellis DL, Nanney LB, Richmond A, Shyr Y, and Robbins JB (2007). Expression of activated Akt in benign nevi, Spitz nevi and melanomas. J Cutan Pathol 34, 593-596.
10. Cheung M, Sharma A, Madhunapantula SV, and Robertson GP (2008). Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68, 3429-3439.
11. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, and Bosenberg M (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41, 544-552.
12. Gray-Schopfer VC, Karasarides M, Hayward R, and Marais R (2007). Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res 67, 122-129.
13. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, and Gambacorti-Passerini C (2008). BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 6, 751-759.
14. Chapman P, Puzanov I, Sosman J, Kim KB, Ribas A, McArthur G, Lee R, Grippo J, Nolop K, and Flaherty K (2009). Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur J Cancer 7(suppl 3), 5.
15. Sondak VK and Smalley K (2009). Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report. Pigment Cell Melanoma Res 22, 386-387.
16. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al. (2009). PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11, R77.
17. Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, Kratzke RA, Dudek A, Potter DA, Woo RA, O'Rourke DM, et al. (2008). Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther 7, 3586-3597.
18. Fargnoli MC, Pike K, Pfeiffer RM, Tsang S, Rozenblum E, Munroe DJ, Golubeva Y, Calista D, Seidenari S, Massi D, et al. (2008). MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol 128, 2485-2490.
19. Tsao H, Goel V, Wu H, Yang G, and Haluska FG (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122, 337-341.
20. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362.
21. Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, and Frankel AE (2005). BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther 4, 1303-1310.
22. Christensen C and Guldberg P (2005). Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene 24, 6292-6302.
23. Hao H, Muniz-Medina VM, Mehta H, Thomas NE, Khazak V, Der CJ, and Shields JM (2007). Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. Mol Cancer Ther 6, 2220-2229.
24. Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et al. (2009). Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 4, e7464.
25. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, et al. (2000).Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540.
26. Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H, Penland S, Arbiser J, Scott G, et al. (2007). Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res 67, 1502-1512.
27. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19, 290-302.
28. Schepsky A, Bruser K, Gunnarsson GJ, Goodall J, Hallsson JH, Goding CR, Steingrimsson E, andHechtA (2006). The microphthalmia-associated transcription factor Mitf interacts with β-catenin to determine target gene expression. Mol Cell Biol 26, 8914-8927.
29. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, and Fisher DE (2004). Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6, 565-576.
30. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, and Yang Y (2003). Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation. J Cell Biol 162, 899-908.
31. Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, Kraus MH, and Aaronson SA (1999). Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 274, 19465-19472.
32. Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE, and Rubin JS (1997). Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad Sci USA 94, 6770-6775.
33. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, and Trent JM (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288.
34. O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, French AD, Dissanayake SK, Indig FE, Bernier M, et al. (2010). The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 29(1), 34-44.
35. Dissanayake SK, Olkhanud PB, O'Connell MP, Carter A, French AD, Camilli TC, Emeche CD, Hewitt KJ, Rosenthal DT, Leotlela PD, et al. (2008). Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res 68, 10205-10214.
36. Larue L, Kumasaka M, and Goding CR (2003). β-Catenin in the melanocyte lineage. Pigment Cell Res 16, 312-317.
37. Martinez-Morales JR, Henrich T, Ramialison M, and Wittbrodt J (2007).Ne genes in the evolution of the neural crest differentiation program. Genome Biol 8, R36.
38. Adameyko I, Lallemend F, Aquino JB, Pereira JA, Topilko P, Muller T, Fritz N, Beljajeva A, Mochii M, Liste I, et al. (2009). Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. Cell 139, 366-379.
39. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, et al. (2009). Growthinhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 11, 720-731.
40. Gray-Schopfer VC, da Rocha Dias S, and Marais R (2005). The role of B-RAF in melanoma. Cancer Metastasis Rev 24, 165-183.
41. 18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 67, 11463-11469.
42. Khaled M, Larribere L, Bille K, Aberdam E, Ortonne JP, Ballotti R, and Bertolotto C (2002). Glycogen synthase kinase 3β is activated by cAMP and plays an active role in the regulation of melanogenesis. J Biol Chem 277, 33690-33697.
43. Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, and Zelger B (2006). Metallothionein-overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer 94, 835-841.
44. Endo T, Yoshikawa M, Ebara M, Kato K, Sunaga M, Fukuda H, Hayasaka A, Kondo F, Sugiura N, and Saisho H (2004). Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. J Gastroenterol 39, 1196-1201.
45. Shimoda R, Achanzar WE, Qu W, Nagamine T, Takagi H, Mori M, and Waalkes MP (2003). Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci 73, 294-300.
46. Poulikakos PI, Zhang C, Bollag G, Shokat KM, and Rosen N (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287), 427-430.
47. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464 (7287), 431-435.